Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases
- 1 August 2017
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 69 (4) , 746-756
Abstract
The p38/MK2 pathway regulates a wide range of biological functions, and thus has most been explored as a therapeutic target for inhibition of severe and chronic inflammatory diseases. Till date, several p38 inhibitors with potent anti-inflammatory effects in pre-clinical models have been discovered, but most of them have failed in clinics due to serious systemic toxicity issues. MK2 is a serine-threonine kinase downstream to p38 and is activated directly through phosphorylation of p38 under stress and inflammatory stimulus. MK2 has been shown to be a direct and essential component in regulating the biosynthesis of pro-inflammatory cytokines. Disruption of MK2 signaling leads to a significant reduction in the level of several pro-inflammatory cytokine production. For these reasons, MK2 has been identified as an alternate molecular target in order to block the pathway with an assumption that this approach would show similar efficacy as that of p38 inhibitors with lesser toxicity concerns. This review briefly summarizes the molecular structure of MK2 and major biological functions in context with its pharmacological modulation to address various inflammatory diseases. It also discusses the points of advantages over p38 inhibition along with recent update in the development of small molecule MK2 inhibitors.Keywords
This publication has 80 references indexed in Scilit:
- DBM1285 Suppresses Tumor Necrosis Factor α Production by Blocking p38 Mitogen-Activated Protein Kinase/Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Signaling PathwayThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Protein Kinases as Small Molecule Inhibitor Targets in InflammationCurrent Medicinal Chemistry, 2007
- Novel strategies for inhibition of the p38 MAPK pathwayTrends in Pharmacological Sciences, 2007
- MAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced ArthritisThe Journal of Immunology, 2006
- Activating p38 MAPK: New Tricks for an Old KinaseCell Cycle, 2005
- The p38 MAP kinase pathway as a therapeutic target in inflammatory diseaseCurrent Opinion in Pharmacology, 2004
- Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritisBioorganic & Medicinal Chemistry Letters, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Inhibition of p38 MAP kinase as a therapeutic strategyImmunopharmacology, 2000
- p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic PotentialsPharmacology & Therapeutics, 1999